Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.39 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA4 | P22748 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6283782 | 0.95 | MAPK1 (0.46) | MAPK1MCL1CHRM2CHRM1CHRM3 | |
| SCHEMBL15692218 | 0.82 | MAPK1 (0.36) | MAPK1MCL1CYP1A2ALDH1A1KMT2A | |
| SCHEMBL374935 | 0.79 | MAPK1 (0.47) | MAPK1MCL1CYP1A2RECQLTHRB | |
| SCHEMBL25061 | 0.79 | MAPK1 (0.47) | MAPK1MCL1CYP1A2RECQLTHRB | |
| SCHEMBL31276435 | 0.79 | MAPK1 (0.47) | MAPK1MCL1CYP1A2RECQLTHRB | |
| SCHEMBL6631827 | 0.78 | MAPK1 (0.35) | MAPK1THRBKDM4E | |
| SCHEMBL31198171 | 0.77 | MAPK1 (0.46) | MAPK1MCL1CYP1A2RECQLTHRB | |
| SCHEMBL8772002 | 0.76 | MAPK1 (0.38) | MAPK1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL1015496 | 0.76 | TLR4 (0.53) | MAPK1CHRM2CHRM1CHRM3ALDH1A1 | |
| SCHEMBL21597573 | 0.76 | MAPK1 (0.36) | MAPK1CHRM2CHRM1CHRM3THRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104230734-B | Synthesis method for alpha-alkylation by visible light catalysis of secondary amine | 中国科学院理化技术研究所 | 2016-06-29 | — | — | CN | disclosed |
| CN-104230734-A | Synthesis method for alpha-alkylation by visible light catalysis of secondary amine | CHINESE ACAD TECH INST PHYSICS | 2014-12-24 | — | — | CN | disclosed |
| US-8309341-B2 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | Les Laboratories Server (FR) | 2012-11-13 | — | — | US | disclosed |
| CN-102459162-A | Novel cyclopentane derivatives | HOFFMANN LA ROCHE | 2012-05-16 | — | — | CN | disclosed |
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | LES LABORATOIRES SERVIER (FR) | 2010-12-30 | — | — | US | disclosed |
| CN-101928241-A | 2-mercaptopentancarboxacid acid derivatives, its preparation method and contain their medicinal compositions | SERVIER LAB | 2010-12-29 | — | — | CN | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-7332622-B2 | Process for preparing optically active nitro compounds and cyano compounds | KANTO KAGUKU KABUSHIKI KAISHA (JP) | 2008-02-19 | — | — | US | disclosed |
| US-6864287-B1 | Derivatives of dicarboxylic acid having pharmaceutical properties | BAYER AKTIENGESELLSCHAFT (DE) | 2005-03-08 | — | — | US | disclosed |
| EP-0755912-B1 | Process for the preparation of 2-substituted cyclopentanones | BAYER AG (DE) | 1999-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100330064-A1 | 2-mercaptocyclopentanecarboxylic acid compounds, a process for their preparation and pharmaceutical compositions containing them | CYP2B6, CYP2A6, MC5R | MAPK1 2157/4885MCL1 1639/4885CHRM2 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.